乙肝疫苗苦参素拉米夫定联合治疗慢性乙型肝炎的临床研究  

Clinical Study on Marine Combined with Lamivudine and Hepatitis B Vaccine in the Treatment of Chronic Hepatitis B

作　　者：贾秋龙 赵治凤 侯良宝[2] 

机构地区：[1]河南省新乡市传染病医院肝病科 [2]河南第一荣康医院放疗科,河南新乡453003

出　　处：《中外医疗》2008年第32期26-27,共2页China & Foreign Medical Treatment

摘　　要：目的探讨乙肝疫苗苦参素拉米夫定联合治疗慢性乙型肝炎的临床疗效。方法随机选择62例慢性乙型肝炎患者分为治疗组31例,苦参素0.2tidpo。疗程7～9个月,乙肝疫苗60ug,每15天1次,皮下注射,疗程12个月,拉米夫定0.1qdpo.疗程12个月。对照组31例单用拉米夫定0.1qdpo。疗程12个月。疗程中定期检测血常规、谷丙转氨酶(ALT)、HBeAg、抗-HBe、HBV、DNA。结果全部患者完成1年治疗。治疗组ALT复常率,HBeAg/抗-HBe血清转换率、HBVDNA阴转率明显高于对照组(分别为80.6%和51.6%,P<0.05;45.2%和19.4%,P<0.05;77.4%和51.6%,P<0.05)。结论乙肝疫苗、苦参素、拉米夫定联合治疗慢性乙型肝炎疗效优于单用拉米夫定。Objective To investigate the clinical therapeutic effect of marine combined with lamivudine and hepatitis B vaccine in the treatment of chronic hepatitis B.Methods 62 chronic hepatitis B patients were enrolled and randomized into the therapy group and the control group.31 cases in the therapy group received marine combined with lamivudine and hepatitis B vaccine（marine 200mg third times daily for 7-9 months,hepatitis B vaccine 60ug one times half month for one year,lamivudine 100mg daily for one year）. 31 cases in the control group received lamivudine 100rag daily for one year.During the treatment blood routine examination of ALT, HBeAg,anti-HBe,HBV DNA were termly checked and measured.Results All 62 patients completed the study.The rates for ALT to recover to normal and the rates for HBeAg/anti-HBe and HBV DNA to change to be negative in combination group were superior to those in lamivudine group.（80.6% vs 51.6%,P〈0.05; 45.2% vs 19.4%,P〈0.05; 77.4% vs 51.6%,P〈0.05）.The efficacy of combination hearpy appeared to be better than lamivudine group.Conclusion Marine combined with lamivudine and hepatitis B vaccine in the treatment of chronic hepatitis B is better than lamivudine group.

关 键 词：乙型肝炎 肝炎病毒 苦参素 乙肝疫苗 拉米夫定 临床疗效 

分 类 号：R392[医药卫生—免疫学]